Reinvent Aliphatic Arsenicals as Reversible Covalent Warheads toward Targeted Kinase Inhibition and Non-acute Promyelocytic Leukemia Cancer Treatment
作者:Yang Zhao、Xinyue Zhao、Lewei Duan、Ruxue Hou、Yuxin Gu、Zhen Liu、Jianbin Chen、Feizhen Wu、Limin Yang、X. Chris Le、Qiuquan Wang、Xiaowen Yan
DOI:10.1021/acs.jmedchem.3c02076
日期:2024.4.11
The success of arsenic in acute promyelocyticleukemia (APL) treatment is hardly transferred to non-APL cancers, mainly due to the low selectivity and weak binding affinity of traditional arsenicals to oncoproteins critical for cancer survival. We present herein the reinvention of aliphatic trivalent arsenicals (As) as reversiblecovalentwarheads of As-based targeting inhibitors toward Bruton’s tyrosine
砷在急性早幼粒细胞白血病(APL)治疗中的成功很难转移到非APL癌症,这主要是由于传统砷对癌症生存至关重要的癌蛋白的选择性低和结合亲和力弱。我们在此提出了脂肪族三价砷 (As) 的重新发明,作为基于 As 的靶向布鲁顿酪氨酸激酶 (BTK) 抑制剂的可逆共价弹头。研究了As弹头的化合价、硫醇保护、甲基化、间隔基长度和尺寸对抑制剂活性的影响。我们发现,与笨重且刚性的芳香族As弹头相比,柔性脂肪族As弹头与优化的导向基团具有良好的相容性,从而实现对BTK的纳摩尔级抑制。优化的As抑制剂有效阻断了BTK介导的致癌信号通路,从而提高了对淋巴瘤细胞和异种移植肿瘤的抗增殖活性。我们的研究提供了一种有前景的策略,能够合理设计新型脂肪族砷基可逆共价抑制剂,用于非 APL 癌症治疗。